ArticleHealthcare policy = Politiques de sante2006
Income-Based Drug Coverage in British Columbia: Lessons for BC and the Rest of Canada.
Article in Healthcare policy = Politiques de sante, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pharmaceutical policies: effects of regulating drug insurance schemes.The Cochrane database of systematic reviews · 2022Pooled it
- Do changes in primary care service use over time differ by neighbourhood income? Population-based longitudinal study in British Columbia, Canada.International journal for equity in health · 2022Article
- Impact of income-based deductibles on drug use and health care utilization among older adults.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2017Article
- Estimating the Cost of Cancer Care in British Columbia and Ontario: A Canadian Inter-Provincial Comparison.Healthcare policy = Politiques de sante · 2017Article
- What impact do prescription drug charges have on efficiency and equity? Evidence from high-income countries.International journal for equity in health · 2008Article
- Influencing Drug Prices through Formulary-Based Policies: Lessons from New Zealand.Healthcare policy = Politiques de sante · 2007Article
- British Columbia's PharmaCare Program: fair or foul?Healthcare policy = Politiques de sante · 2006Article
- Income-based drug coverage in british columbia: towards an understanding of the policy.Healthcare policy = Politiques de sante · 2006Article
- Income-based drug coverage in British Columbia: the impact on the distribution of financial burden.Healthcare policy = Politiques de sante · 2006Article
- Income-based drug coverage in British Columbia: the impact on private and public expenditures.Healthcare policy = Politiques de sante · 2006Article
- Income-based drug coverage in British Columbia: the impact on access to medicines.Healthcare policy = Politiques de sante · 2006Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn May 2003, the government of British Columbia adopted income-based pharmacare, replacing an age-based drug benefits program. Stated policy goals included reducing government spending, maintaining or enhancing access to medicines and improving financial equity. The province's experience on these policy dimensions can inform policy making in other jurisdictions and offers insight into priorities for Canada's National Pharmaceuticals Strategy.
methodThe research team created an anonymized database with information about drug use, private and public expenditure and household income for all residents of British Columbia from 1996 to 2004. This database was used to evaluate the impact of the policy on trends in drug expenditures, utilization and sources of payment for seniors and non-seniors of different income levels.
resultsIn the immediate term, Fair PharmaCare appears to have met many of its policy goals. Government spending was reduced. Access to medicines was maintained (though not enhanced). And the distributions of private and public expenditures were brought more closely in line with distribution of income. Long-run impacts depend largely on how a reduced role for government affects trends in costs, access and equity. Early indications suggest that a larger role for government may be needed to maintain performance on desired policy objectives over time.
conclusionIn the long run, there is reason for setting a new national standard for pharmacare that increases, not decreases, the share of publicly covered spending in every province. The federal government could play a key role by helping provinces increase public funding for prescription drugs and thereby facilitate cost control, maintain access to medicines and enhance financial equity.
Identifiers
19305708PMC2585436What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.